Improved Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Protocol for the Treatment of Epstein Barr Virus T/NK Lymphoproliferative Disease (EBV-T/NK LPD) and Prevention of Post Transplant Graft-versus-host Disease

To investigate whether the addition of recombinant humanized anti-CD25 monoclonal antibody to the conventional EBV-T/NK LPD conditioning regimen can prevent acute and chronic GVHD after transplantation, improve the severity of GVHD and have a corresponding impact on other related post-transplant complications such as poor engraftment, thrombotic microvascular disease, early EBV reactivation and relapse.

NCT Number	NCT07029958
Lead Sponsor	Beijing Children's Hospital
Conditions	EBV-T/NK LPD
Enrollment	48 participants
Start Date	2024-11-12
Primary Completion	2029-10-30 (estimated)
Study Completion	2029-10-30 (estimated)
Updated on ClinicalTrials.gov	2025-06-19